Please assess the completion status of the following clinical trial:

Trial Title: Afatinib Genomic Landscape

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria/Exclusion Criteria:~* Diagnosis of metastatic stage IIIB/IV lung adenocarcinoma~* Presence of known sensitizing mutations in EGFR TK domain (exon 19 deletion and L858R)~* Absence of known resistant mutations in the EGFR TK domain (T790M)~* Consented to HRPO # 201305031 (Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information from Patients with Thoracic Malignancies, Suspected Thoracic Malignancies, or Mesothelioma)~* No prior treatment for this malignancy~* No prior localized therapy to the biopsy site~* Planned treatment with standard of care afatinib at 40 mg QD (daily)~* Not pregnant or breastfeeding~* At least 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).